AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

Dual blocking SHP2 and FGFR2 can not only promote the targeted tumor-killing effects and overcome FGFR2 inhibitor resistance caused by feedback activation, but also activate T cell-mediated anti-tumor ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products ...

Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate discovered by Daiichi Sankyo.

Indication expands to include treatment-naïve patients - - The 2021 conditional approval in previously treated patients converted to ful ...

AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients ...

Centre for Proteomic Research, School of Biological Sciences and Institute for Life Sciences, University of Southampton, Building 85, Southampton SO17 1BJ ,U.K. Centre for Cancer Immunology and ...

School of Manufacture Science and Engineering, Key Laboratory of Testing Technology for Manufacturing Process, Ministry of Education, Southwest University of Science and Technology, Mianyang 621010, ...

KYIV, Jan 4 (Reuters) - Russian forces continue to launch attacks near the Ukrainian city of Pokrovsk in an effort to bypass it from the south and cut off supply routes to Ukraine's troops, the ...

for first-line treatment of advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations. This approval marks a significant milestone in the treatment of EGFR-mutated NSCLC. “For people ...